Penumbra Inc (PEN)

$203.73

-0.31

(-0.15%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $199.93
    $204.58
    $203.73
    downward going graph

    1.87%

    Downside

    Day's Volatility :2.27%

    Upside

    0.42%

    downward going graph
  • $148.00
    $302.00
    $203.73
    downward going graph

    27.35%

    Downside

    52 Weeks Volatility :50.99%

    Upside

    32.54%

    downward going graph

Returns

PeriodPenumbra IncSector (Health Care)Index (Russel 2000)
3 Months
7.82%
5.1%
0.0%
6 Months
-19.44%
4.9%
0.0%
1 Year
-29.63%
16.6%
0.0%
3 Years
-24.59%
13.2%
-22.3%

Highlights

Market Capitalization
7.9B
Book Value
$29.9
Earnings Per Share (EPS)
0.35
PE Ratio
582.09
PEG Ratio
-62.27
Wall Street Target Price
201.33
Profit Margin
1.26%
Operating Margin TTM
-1.34%
Return On Assets TTM
3.32%
Return On Equity TTM
1.28%
Revenue TTM
1.1B
Revenue Per Share TTM
29.33
Quarterly Revenue Growth YOY
14.499999999999998%
Gross Profit TTM
535.2M
EBITDA
105.6M
Diluted Eps TTM
0.35
Quarterly Earnings Growth YOY
0.27
EPS Estimate Current Year
2.62
EPS Estimate Next Year
3.61
EPS Estimate Current Quarter
0.56
EPS Estimate Next Quarter
0.88

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Penumbra Inc(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
15
Hold
6
6
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 1.18%

Current $203.73
Target $201.33

Company Financials

FY18Y/Y Change
Revenue
444.9M
↑ 33.31%
Net Income
6.6M
↑ 41.74%
Net Profit Margin
1.48%
↑ 0.08%
FY19Y/Y Change
Revenue
547.4M
↑ 23.03%
Net Income
48.5M
↑ 634.1%
Net Profit Margin
8.85%
↑ 7.37%
FY20Y/Y Change
Revenue
560.4M
↑ 2.38%
Net Income
-19.3M
↓ 139.74%
Net Profit Margin
-3.44%
↓ 12.29%
FY21Y/Y Change
Revenue
747.6M
↑ 33.4%
Net Income
2.6M
↓ 113.62%
Net Profit Margin
0.35%
↑ 3.79%
FY22Y/Y Change
Revenue
847.1M
↑ 13.32%
Net Income
-2.0M
↓ 176.32%
Net Profit Margin
-0.24%
↓ 0.59%
FY23Y/Y Change
Revenue
1.1B
↑ 24.95%
Net Income
91.0M
↓ 4643.16%
Net Profit Margin
8.59%
↑ 8.83%
Q1 FY23Q/Q Change
Revenue
241.4M
↑ 9.12%
Net Income
8.6M
↑ 120.84%
Net Profit Margin
3.55%
↑ 1.8%
Q2 FY23Q/Q Change
Revenue
261.5M
↑ 8.33%
Net Income
19.0M
↑ 121.44%
Net Profit Margin
7.25%
↑ 3.7%
Q3 FY23Q/Q Change
Revenue
270.9M
↑ 3.61%
Net Income
9.2M
↓ 51.4%
Net Profit Margin
3.4%
↓ 3.85%
Q4 FY23Q/Q Change
Revenue
284.7M
↑ 5.07%
Net Income
54.2M
↑ 488.43%
Net Profit Margin
19.05%
↑ 15.65%
Q1 FY24Q/Q Change
Revenue
278.7M
↓ 2.12%
Net Income
11.0M
↓ 79.71%
Net Profit Margin
3.95%
↓ 15.1%
Q2 FY24Q/Q Change
Revenue
299.4M
↑ 7.45%
Net Income
-60.2M
↓ 647.17%
Net Profit Margin
-20.11%
↓ 24.06%
FY18Y/Y Change
Total Assets
515.0M
↑ 8.04%
Total Liabilities
92.6M
↑ 21.42%
FY19Y/Y Change
Total Assets
665.9M
↑ 29.3%
Total Liabilities
180.3M
↑ 94.71%
FY20Y/Y Change
Total Assets
823.0M
↑ 23.59%
Total Liabilities
185.2M
↑ 2.72%
FY21Y/Y Change
Total Assets
1.2B
↑ 51.19%
Total Liabilities
290.3M
↑ 56.77%
FY22Y/Y Change
Total Assets
1.4B
↑ 10.18%
Total Liabilities
372.0M
↑ 28.14%
FY23Y/Y Change
Total Assets
1.6B
↑ 13.53%
Total Liabilities
377.4M
↑ 1.43%
Q1 FY23Q/Q Change
Total Assets
1.4B
↑ 1.78%
Total Liabilities
370.8M
↓ 0.32%
Q2 FY23Q/Q Change
Total Assets
1.4B
↑ 2.67%
Total Liabilities
366.0M
↓ 1.31%
Q3 FY23Q/Q Change
Total Assets
1.5B
↑ 2.5%
Total Liabilities
364.2M
↓ 0.48%
Q4 FY23Q/Q Change
Total Assets
1.6B
↑ 5.99%
Total Liabilities
377.4M
↑ 3.6%
Q1 FY24Q/Q Change
Total Assets
1.6B
↑ 1.51%
Total Liabilities
376.3M
↓ 0.28%
Q2 FY24Q/Q Change
Total Assets
1.5B
↓ 2.87%
Total Liabilities
373.3M
↓ 0.79%
FY18Y/Y Change
Operating Cash Flow
28.8M
↑ 127.0%
Investing Cash Flow
-385.0K
↓ 99.5%
Financing Cash Flow
-9.8M
↓ 109.41%
FY19Y/Y Change
Operating Cash Flow
26.7M
↓ 7.48%
Investing Cash Flow
-12.7M
↑ 3201.56%
Financing Cash Flow
-9.0M
↓ 8.72%
FY20Y/Y Change
Operating Cash Flow
-33.2M
↓ 224.73%
Investing Cash Flow
-104.1M
↑ 719.36%
Financing Cash Flow
134.9M
↓ 1605.94%
FY21Y/Y Change
Operating Cash Flow
9.5M
↓ 128.58%
Investing Cash Flow
-21.7M
↓ 79.13%
Financing Cash Flow
836.0K
↓ 99.38%
FY22Y/Y Change
Operating Cash Flow
-55.7M
↓ 685.78%
Investing Cash Flow
54.8M
↓ 352.08%
Financing Cash Flow
11.6M
↑ 1290.19%
Q1 FY23Q/Q Change
Operating Cash Flow
13.1M
↑ 881.97%
Investing Cash Flow
10.7M
↓ 80.45%
Financing Cash Flow
1.4M
↓ 76.01%
Q2 FY23Q/Q Change
Operating Cash Flow
17.1M
↑ 30.24%
Investing Cash Flow
-6.7M
↓ 162.28%
Financing Cash Flow
8.7M
↑ 531.83%
Q3 FY23Q/Q Change
Operating Cash Flow
30.8M
↑ 80.38%
Investing Cash Flow
-40.4M
↑ 504.95%
Financing Cash Flow
212.0K
↓ 97.56%

Technicals Summary

Sell

Neutral

Buy

Penumbra Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Penumbra Inc
Penumbra Inc
24.5%
-19.44%
-29.63%
-24.59%
49.61%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Penumbra Inc
Penumbra Inc
582.09
582.09
-62.27
2.62
0.01
0.03
NA
29.9
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Penumbra Inc
Penumbra Inc
Buy
$7.9B
49.61%
582.09
1.26%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Penumbra Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 278.65M → 299.40M (in $), with an average increase of 6.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 54.21M → -60.2M (in $), with an average decrease of 363.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 81.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 105.5%

Institutional Holdings

  • FMR Inc

    14.87%

  • BlackRock Inc

    10.95%

  • Vanguard Group Inc

    9.52%

  • T. Rowe Price Associates, Inc.

    7.79%

  • Champlain Investment Partners, LLC

    3.31%

  • State Street Corporation

    3.10%

Company Information

penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.

Organization
Penumbra Inc
Employees
4200
CEO
Mr. Adam Elsesser
Industry
Health Technology

Discover More

FAQs